LILRB2/CD85d/ILT-4 蛋白, Human (HEK293, His-Avi)

LILRB2/CD85d/ILT-4 Protein, a receptor for class I MHC antigens, recognizes a broad range of HLA alleles. It crucially down-regulates immune responses, establishing tolerance. Specific recognition of HLA-G, with a self-peptide, leads to type 1 regulatory T cell and myeloid-derived suppressor cell differentiation, essential for maternal-fetal tolerance. LILRB2 competes with CD8A, inhibits FCGR1A-mediated responses, and interacts with PTPN6 when phosphorylated. Direct interactions with peptide-bound HLA-G-B2M and HLA-F-B2M emphasize its immune modulation role. LILRB2/CD85d/ILT-4 Protein, Human (HEK293, His-Avi) is the recombinant human-derived LILRB2/CD85d/ILT-4 protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of LILRB2/CD85d/ILT-4 Protein, Human (HEK293, His-Avi) is 437 a.a., with molecular weight of 70-75 kDa.

LILRB2/CD85d/ILT-4 蛋白作为 I 类 MHC 抗原的受体，可广泛识别 HLA-A、HLA-B、HLA-C、HLA-G 和 HLA-F 等位基因。它在免疫反应下调和耐受性建立中起着至关重要的作用。具体来说，它识别与 B2M/β-2 微球蛋白和九聚体自肽复合的 HLA-G，导致 1 型调节性 T 细胞和骨髓源性抑制细胞的分化，这对于维持母胎耐受性至关重要。LILRB2 与 CD8A 竞争与 I 类 MHC 抗原的结合，并抑制 FCGR1A 介导的细胞反应，包括蛋白质磷酸化和细胞内钙离子的动员。此外，它在磷酸化时与 PTPN6 相互作用并与 FCGR1A 结合。与肽结合的 HLA-G-B2M 和 HLA-F-B2M 的直接相互作用进一步凸显了其参与免疫调节。

Human

HEK293

C-Avi;C-His

Q8N423 (Q22-H458)

10288  [NCBI]

70-75 kDa

Greater than 95% as determined by Tris-Bis PAGE.

<1 EU/μg, determined by LAL method.